Stable compositions of functional ingredients and methods of making the same

A composition for oral consumption, comprising:

• an aqueous suspension, comprising:
• a first plurality of active ingredients selected from the group consisting of methylphenidate, dextroamphetamine, amphetamine, dextroamphetamine, Caffeine, nicotine, Methamphetamine, 3,4-Methylenedioxymethamphetamine, Methylenedioxypyrovalerone, Mephedrone, Phenylpropanolamine, Propylhexedrine, Pseudoephedrine, Catha edulis, Modafinil, xanthine derivatives, theophylline, and theobromine, wherein:
• the first plurality of active ingredients are soluble in the aqueous suspension;
• and
• one or more nanoparticles, wherein:
• the one or more nanoparticles encapsulate a second plurality of active ingredient selected from the group consisting of Echinacea purpurea, Echinacea angustifolia, Echinacea pallida, Acmella oleracea, Helichrysum umbraculigerum, Radula marginata, kava, kanna, black truffle, Syzygium aromaticum, Rosmarinus oficinalis, Sceletium tortuosum, Holy basil, Oregano, Lavender, Cinnamon, Malabathrum, Cananga odorata, Ginkgo Biloba, Bacopa, and Rhodiola rosea, Ashwagandha, Astragalus, Chaga, Cordyceps, Corydalis, Curcumin, Damiana, Eleuthero, Ginger root, Ginseng, Gotu Kola, Lion's Mane, Maca, Passionflower, Saffron, Schisandra, St. John's Wort, Turmeric, Turkey Tail, Valerian root, and Yohimbe;
• the one or more nanoparticles further comprises:
• a plurality of emulsifying agents selected from the group consisting of an extract of Quillaja, extract of Licorice, polysorbate 20, polysorbate 40, polysorbate 45, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 81 and polysorbate 85, polyglyceryl, gum acacia, Polyglycerol polyricinoleate, sorbitan 85, sorbitan 65, sorbitan 83, sorbitan 80, sorbitan 60, sorbitan 40, Xanthan gum, sorbitol, mannitol, glycerol, sodium alginate, lecithin, chemically modified lecithin, purified components of lecithin, phosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, and cardiolipin, hydrogenated soybean phosphatidylcholine, hydrogenated soybean phosphatidylcholine, tocopherol polyethylene glycol succinate, fatty acid mono-and di-glycerides, acetic acid esters of mono-and di-glycerides, lactic acid esters of mono-and di-glycerides, citric acid esters of mono-and di-glycerides, diacetyl tartaric acid ester of mono-and di-glycerides, triglycerol monooleate, hexaglycerol octasterate, polyglycerol esters of oleic acid, decaglycerol mono-and di-oleate, glyceryl caprylate, glyceryl caprate, glyceryl caprate/caprylate, glyceryl monooleate, glycerly monostearate, poloxamers, milk proteins, casein, pea proteins, whey proteins, collagen, sodium stearoyl lactylate, extract of bacopa, withaferin A, withaferin B, withanolide A, withanolide B, withanolide C, withanolide D, withanolide E, withanolide F, withanolide G, withanoside I, withanoside II, withanoside III, withanoside IV, withanoside V, withanoside VI, withanoside VII, bacopaside I, bacopaside II, bacopaside III, bacopaside IV, bacopaside V, bacopaside VI, bacopaside VII, bacopaside VIII, bacopaside IX, bacopaside X, bacopaside XI, bacopaside XII, bacopaside N1, bacopaside N2, bacosaponin A, bacosaponin B, bacosaponin C, bacosaponin D, bacosaponin E, bacosaponin F, bacosaponin G, bacosaponin H, bacoside A3, bacosine, or combinations thereof;
• the one or more nanoparticles solubilize the second plurality of active ingredients in the aqueous suspension;
• the one or more nanoparticles have a Z-average diameter between 50 to 950 nanometers;
• the one or more nanoparticles has a net negative charge that is-15 mV or lower;
• the one or more nanoparticles comprise a crosslinked hydrophilic polymer network at an interface of the one or more nanoparticles;
• the Z-average diameter of the one or more nanoparticles changes less than 20% when the aqueous suspension is incubated at 40° C. for four weeks;
• and
• the Z-average diameter of the one or more nanoparticles changes less than 20% when the aqueous suspension is incubated at 90° C. for 30 minutes.